Prognostic Effect of BRAF and KRAS Mutations in Patients With ...

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Prognostic Effect of BRAF and KRAS Mutations in Patients ... - PubMed

BRAF V600E and KRAS mutations were significantly associated with shorter DFS and OS in patients with microsatellite-stable tumors but not in patients with MSI ...

Prognostic Impact of BRAF and KRAS Mutation in Patients ... - PubMed

BRAF mutation is a marker of poor prognosis in patients with appendiceal and colorectal peritoneal metastases scheduled for CRS and HIPEC, whereas survival ...

Prognostic effect of RAS/BRAF mutations in patients (pts) with ...

The numerically higher mOS in pts with KRAS G12C and non-codon 12 KRAS mutations merit further biologic characterization with functional assays.

Prognostic Effect of BRAF and KRAS Mutations in Patients

Prognostic Effect of BRAF and KRAS Mutations in Patients. With Stage III Colon Cancer Treated With Leucovorin,. Fluorouracil, and Oxaliplatin ...

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS ...

Conclusions: In a pooled analysis of resected stage III colon cancer patients receiving adjuvant FOLFOX, BRAF or KRAS mutations are ...

Prognostic Impact of BRAF and KRAS Mutation in Patients with ...

Results. Mutation in KRAS was present in 51/111 (46%), and mutated BRAF was found in 10/92 (11%). There was no difference in overall survival ...

The prognostic significance of KRAS and BRAF mutation status in ...

BRAF mutation, rather than KRAS, was a significant prognostic factor in Korean CRC patients at both early and advanced stages.

Incidence and prognostic impact of KRAS and BRAF mutation in ...

Molecular biomarkers offer the potential for refining prognostic determinants in patients undergoing cancer surgery. Among patients with ...

CMS-dependent prognostic impact of KRAS and BRAF V600E ...

BRAFV600E and KRAS mutations were both associated with inferior 5-year overall survival (OS) exclusively in MSS tumors (BRAFV600E mutation versus KRAS/BRAF wild ...

CMS-dependent prognostic impact of KRAS and BRAFV600E ...

BRAFV600E and KRAS mutations were both associated with inferior 5-year overall survival (OS) exclusively in MSS tumors (BRAFV600E mutation versus KRAS/BRAF wild ...

BRAF and KRAS mutations in metastatic colorectal cancer

The BRAF mutation is also a strong indicator of poor prognosis in mCRC; the addition of an anti-EGFR agent had a detrimental effect on survival ...

Prognostic impact of mutation profiling in patients with stage II and III ...

KRAS, BRAF and NRAS mutations do not have major prognostic value in stage II and III colon cancer, subtypes of gene mutations should be further investigated.

Prognostic Effect of BRAF and KRAS Mutations in Patients With ...

BRAF V600E and KRAS mutations were significantly associated with shorter disease-free and overall survival in patients with microsatellite-stable tumors but not ...

KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers ...

However, its prognosis impact and the predictive potential for first-line standard chemotherapy remains unclear. On the other hand, V600E mutation is the most ...

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as ...

Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors.

Prognostic effect of specific RAS/BRAF mutations in patients (pts ...

Altmetric. Citations. Article Citation ... Prognostic effect of specific RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer ( ...

Prognostic value of specific KRAS mutations in patients with ...

KRAS mutations occurred in 172 patients (47.5%) out of the 362 analyzed. Two different prognostic groups of KRAS mutation subtypes were ...

Specific Mutations in KRAS Codons 12 and 13, and Patient ...

To assess prognostic roles of KRAS mutations in colorectal cancer, BRAF mutation status must be controlled because BRAF-mutated cancers are associated with ...

Different prognostic values of KRAS exon 2 submutations and BRAF ...

BRAFV600E, KRAS G12C, and G13D mutations are associated with shorter SAR in patients resected from a stage III MSS CC. Abstract. Background. The ...